Study Title and Description
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.|
|Author||Jolly EE., Bjarnason NH., Neven P., Plouffe L., Johnston CC., Watts SD., Arnaud CD., Mason TM., Crans G., Akers R., Draper MW.|
|Country||Department of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa, Canada.|
|Year||-- Not Found --|
Pubmed ID: 12851517
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.